Patient and caregiver benefit‐risk preferences for nonmetastatic castration‐resistant prostate cancer treatment-Reference-Cited by-同舟云学术

Patient and caregiver benefit‐risk preferences for nonmetastatic castration‐resistant prostate cancer treatment

Published:2020-07-29 Issue:18 Volume:9 Page:6586-6596
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Srinivas Sandy¹,Mohamed Ateesha F.²,Appukkuttan Sreevalsa²,Botteman Marc³^ORCID,Ng Xinyi³^ORCID,Joshi Namita³^ORCID,Tsai Jui‐Hua³,Fang Jarjieh³,Waldeck A. Reginald²,Simmons Stacey J.²

Affiliation:

1. Stanford University Medical Center Palo Alto CA USA

2. Bayer U.S. LLC Whippany NJ USA

3. Pharmerit International, LP Bethesda MD USA

Funder

Bayer U.S LLC

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.3321

Reference43 articles.

1. American Cancer Society.Key Statistics for Prostate Cancer 2019.https://www.cancer.org/cancer/prostate‐cancer/about/key‐statistics.html. Accessed September 4 2019.

2. Castration-Resistant Prostate Cancer: AUA Guideline

3. Decision-making Processes among Prostate Cancer Survivors with Rising PSA Levels

4. Prevalence of Prostate Cancer Clinical States and Mortality in the United States: Estimates Using a Dynamic Progression Model

5. Clinical predictors of survival in men with castration-resistant prostate cancer

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Re: Wesley R. Armstrong, Amar U. Kishan, Kiara M. Booker, et al. Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography on Prostate Cancer Salvage Radiotherapy Management: Results from a Prospective Multicenter Randomized Phase 3 Trial (PSMA-SRT NCT03582774). Eur Urol 2024;86:52–60;European Urology;2024-08

2. Patient versus physician preferences for lipid‐lowering drug therapy: A discrete choice experiment;Health Expectations;2024-04

3. Drug–drug interaction potential among patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with novel androgen receptor inhibitors;Expert Review of Anticancer Therapy;2024-03-12

4. Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS;The Oncologist;2024-02-23

5. Adverse events related to darolutamide treatment: analysis of "real life" data from EudraVigilance and the Food and Drug Administration database entries;Minerva Urology and Nephrology;2023-09